Echo Revolve Microscope
Forecast New Requirement Updated
- Agency
-
Food and Drug Administration
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $25,000 to $250,000
- Set-aside
- No set-aside
Forecast facts
- Anticipated award
- NAICS code
- 333314 Optical Instrument and Lens Manufacturing
- Points of contact
-
- CBER Acquisition Liaison cberacquisitions@fda.hhs.gov
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The Food and Drug Administration is procuring an Echo Revolve R4 microscope, an upright and inverted dual-mode imaging instrument capable of brightfield and multi-channel fluorescence imaging for cultured cells and tissue specimens used in gene therapy product characterization and evaluation. The microscope will replace a brightfield-only microscope at the Kemaladewi Laboratory, Gene Therapy Immunology Branch, expanding imaging capabilities to support research and regulatory science activities. Estimated solicitation release is May 1, 2027, with award targeted for September 1, 2027.
The estimated award value ranges from $25,000 to $250,000. Place of performance is the Kemaladewi Laboratory within the FDA's Gene Therapy Immunology Branch. Inquiries should be directed to the FDA's Contracting and Business Services Mailbox at cberacquisitions@fda.hhs.gov.
Forecast text
The REVOLVE R4 microscope provides both upright and inverted imaging in a single instrument, enabling versatile brightfield and multi-channel fluorescence imaging of cultured cells and tissue specimens used in the characterization and evaluation of gene therapy products while reducing the need for multiple microscopes. It will replace a brightfield-only microscope currently housed in the Kemaladewi Laboratory, Gene Therapy Immunology Branch (GTIB), significantly expanding imaging capabilities and ensuring continued support for research and regulatory science activities.
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast